Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 19 (2) , 225-230
- https://doi.org/10.3109/00498258909034695
Abstract
1. Dark agouti (DA) and Lewis rat strains, which show a genetic polymorphism for debrisoquine-4-hydroxylation, were treated either with a single dose of ochratoxin A (OA) or for 8 weeks with 5 doses per week. Levels of OA and its 4-hydroxy metabolite (4-hydroxy-OA) excreted in urine were determined. 2. At all doses, the metabolic ratio of OA: 4-hydroxy-OA was two to five times greater in DA than in Lewis rats, as was the metabolic ratio of debrisoquine: 4-hydroxy-debrisoquine. These results are consistent with our previous findings in vitro that hepatic and renal OA 4-hydroxylase activity is three to four times lower in DA than in Lewis rats. These data give further support to the possible co-segregation of genes regulating OA and debrisoquine 4-hydroxylation.This publication has 6 references indexed in Scilit:
- Ochratoxin A in human blood in relation to Balkan endemic nephropathy and urinary system tumours in BulgariaFood Additives & Contaminants: Part A, 1988
- Ochratoxin A contamination of cereals in an area of high incidence of Balkan endemic nephropathy in BulgariaFood Additives & Contaminants: Part A, 1985
- Lack of relationship between debrisoquine 4-hydroxylation and other cytochrome P-450 dependent reactions in rat and human liverBiochemical Pharmacology, 1985
- Metabolic oxidation phenotypes as markers for susceptibility to lung cancerNature, 1984
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981
- Some observations on the oxidation phenotype status of Nigerian patients presenting with cancerCancer Letters, 1981